Specifically, pharmacological activation of PERK with subsequent phosphorylation of eIF2α can induce tumor growth arrest both in vitro and in vivo, primarily through the inhibition of cyclin D1 and cell cycle arrest at the G1 phase [247,248,249]. Here, EIF2AK3 is linked to neoplasm.